Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
According to Morgan Stanley , combined sales of injections that curb appetites and promote weight loss could reach an estimated $105 billion by 2030. Viking Therapeutics (NASDAQ: VKTX) is still a clinical-stage drugmaker that's developing an anti-obesity candidate called VK2735 that appears competitive with a similar drug the U.S. Food and Drug Administration (FDA) approved in 2022 called tirzepatide. Marketed by Eli Lilly as Mounjaro for diabetes and Zepbound for weight management, tirzepatide sales have already exceeded $17.3 billion annually. Many potential consumers of weight-management drugs are holding off because they don't want to jab themselves with a needle each week. Providing an easy-to-swallow solution for these patients could lead to billions in annual revenue, but clinical development of oral anti-obesity drugs has been more than a little challenging. Why Roche's oral weight-management drug probably isn't going anywhere In July, Roche (OTC: RHHBY) , a global pha
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]Yahoo! Finance
- Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. [Yahoo! Finance]Yahoo! Finance
- Why Investors Plowed Into Viking Therapeutics Stock Today [Yahoo! Finance]Yahoo! Finance
- Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $105.00 price target on the stock.MarketBeat
VKTX
Earnings
- 7/24/24 - Beat
VKTX
Sec Filings
- 8/22/24 - Form 4
- 8/22/24 - Form 4
- 8/21/24 - Form 144
- VKTX's page on the SEC website